by Eric Christianson | Mar 8, 2026 | Endocrine Medication and Disease State Clinical Pearls
Diabetes management can be quite complex as it is a progressive disease, and goals can change depending on a variety of patient factors. In general, the ADA suggests an A1C goal of <7%, but in some cases, less stringent goals like <8% may be appropriate. The...
by Eric Christianson | Jul 30, 2025 | Endocrine Medication and Disease State Clinical Pearls
Ertugliflozin was first approved in 2017 for the treatment of type 2 diabetes. This medication is an SGLT2 inhibitor that prevents the resorption of glucose back into systemic circulation. It has been shown to be effective in lowering A1c and managing diabetes. In...
by Eric Christianson | Jan 26, 2025 | Endocrine Medication and Disease State Clinical Pearls
Type II diabetes is a complicated disease state that often requires a combination of medications to control. However, some combinations of antidiabetes medications, such as sulfonylureas and basal insulin, may lead to unintended adverse effects. In this article, we...
by Eric Christianson | Jan 12, 2025 | Endocrine Medication and Disease State Clinical Pearls
Treating patients with type II diabetes often requires an array of medications to control blood sugar and manage various comorbidities. Understanding possible drug-drug and drug-disease interactions between medications is extremely important for optimizing medication...
by Eric Christianson | Dec 29, 2024 | Endocrine Medication and Disease State Clinical Pearls
Reducing diabetes medications in geriatric patients with low A1c involves careful consideration of the risks and benefits of continued intensive glycemic control. In older adults, particularly those with multiple comorbidities, frailty, or limited life expectancy,...
by Eric Christianson | Nov 24, 2024 | Clinical Pharmacy News and New Drug Updates, Endocrine Medication and Disease State Clinical Pearls
Insulin icodec may have a new competitor in the near future. Insulin efsitora is another once-weekly insulin currently undergoing phase 3 clinical trials, with Lilly’s 3rd phase being termed the QWINT trials (Once Weekly (QW) Insulin Therapy (INT)). These trials are...
